Last reviewed · How we verify

Tobramycin + Dexamethasone — Competitive Intelligence Brief

Tobramycin + Dexamethasone (Tobramycin + Dexamethasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic + corticosteroid combination. Area: Ophthalmology / Infectious Disease.

marketed Antibiotic + corticosteroid combination Bacterial 30S ribosomal subunit (tobramycin); glucocorticoid receptor (dexamethasone) Ophthalmology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Tobramycin + Dexamethasone (Tobramycin + Dexamethasone) — Umm Al-Qura University. Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tobramycin + Dexamethasone TARGET Tobramycin + Dexamethasone Umm Al-Qura University marketed Antibiotic + corticosteroid combination Bacterial 30S ribosomal subunit (tobramycin); glucocorticoid receptor (dexamethasone)
Antibiotics + Corticosteroids Antibiotics + Corticosteroids George Washington University marketed Antibiotic + Corticosteroid combination
moxifloxacin / dexamethasone moxifloxacin / dexamethasone Federal University of São Paulo marketed Fluoroquinolone antibiotic + corticosteroid combination Bacterial DNA gyrase, topoisomerase IV, glucocorticoid receptor
Ciprofloxacin HCl and Hydrocortisone Ciprofloxacin HCl and Hydrocortisone Farmoquimica S.A. phase 3 Fluoroquinolone antibiotic + corticosteroid combination Bacterial DNA gyrase and topoisomerase IV; glucocorticoid receptor
Moxifloxacin / Dexamethasone Ophthalmic Solution Moxifloxacin / Dexamethasone Ophthalmic Solution Laboratorios Sophia S.A de C.V. phase 3 Fluoroquinolone antibiotic + Corticosteroid combination Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone)
Levofloxacin + dexamethasone followed by dexamethasone Levofloxacin + dexamethasone followed by dexamethasone NTC srl phase 3 Fluoroquinolone antibiotic + corticosteroid combination Bacterial DNA gyrase, topoisomerase IV (levofloxacin); glucocorticoid receptor (dexamethasone)
Clindamycin+Dexamethasone Clindamycin+Dexamethasone Shahid Beheshti University of Medical Sciences phase 3 Antibiotic + Corticosteroid combination Bacterial 50S ribosome (clindamycin); Glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic + corticosteroid combination class)

  1. Umm Al-Qura University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tobramycin + Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/tobramycin-dexamethasone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing